Join to view full profile
1365 Clifton Rd NEBldg CAtlanta, GA 30322
Phone+1 404-778-7408
Dr. Blum is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. William Blum is an oncologist based in Atlanta, GA, specializing in hematologic oncology, marrow/ stem cell transplantation, and leukemia. He is the Director of the Adult Acute Leukemia Program at Winship Cancer Institute of Emory University and a member of the bone marrow transplant/ cell therapy program as well. Dr. Blum is an expert in the management of myeloid and lymphoid disorders, and a leading author in phase 1, phase 2, and phase 3 trials in this area.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2000 - 2003
University of Virginia Medical CenterResidency, Internal Medicine, 1997 - 2000
Medical College of Georgia at Augusta UniversityClass of 1997
Certifications & Licensure
GA State Medical License 2017 - 2026
OH State Medical License 2003 - 2019
MO State Medical License 2003 - 2004
VA State Medical License 1997 - 2002
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
Publications & Presentations
PubMed
- Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.Fieke W Hoff, Joshua F Zeidner, Geeta Torlapati, Deedra Nicolet, Krzysztof Mrózek
American Journal of Hematology. 2026-09-01 - 1 citationsRisk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.Curtis A Lachowiez, Joshua F Zeidner, Jad Othman, Andy Kaempf, Seongseok Yun
Journal of Clinical Oncology. 2026-09-01 - Epigenetic markers expand genetic risk estimation in acute myeloid leukemia.Salma B Abdelbaky, Brian Giacopelli, Jessica Kohlschmidt, Kyoko Yamaguchi, Krzysztof Mrózek
Blood. 2026-08-25
Abstracts/Posters
- Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...William Blum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant AbstractWilliam Blum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master TrialWilliam Blum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Children’s Healthcare of Atlanta Opens First Clinical Trial for New Therapy Targeting LeukemiaApril 12th, 2023
COVID-19 Timeline Exposes Falsehood of US and US Lackey Australian Anti-China Blame GameMay 21st, 2020
Per Capita Covid-19 Deaths in Anglosphere 5-Eyes Intelligence-Sharing Nations Correlate with Neoliberal GreedMay 17th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: